By tracking your weight trends, symptoms, and labs, your clinician can see whats working, troubleshoot plateaus, and provide strategies to prevent rebound weight gain
And, you know, I think its really its a bit treacherous if were out talking about things that arent rooted in fact and are based on guts, and hunches, and feelings, and personal experiences, which is fine, but if were making decisions on stuff, we really kind of have to do two things: 1., we have to separate church and state as much as possible thats one way to think about it and 2nd, we have to just stay tethered to science and fact
Take JPMorgan Chase , for example
[4] A marketing trade name for one brand of afamelanotide was approved in 2010 by the European Medicines Agency (EMA) Name Review Group (NRG) and the Agency's Committee for Human Medicinal Products (CHMP) as Scenesse (pronounced "sen-esse")
Preclinical data presented at ADA 2024 showed that HM15275 delivered superior weight loss efficacy compared to semaglutide (Wegovy) and tirzepatide (Zepbound), with relatively less reductions in lean mass
The peptide may have degraded from improper storage
.png)
